Tirzepatide, a dual GIP GLP 1 receptor co agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Cardiovascular Diabetology Springer Nature Link PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar retatrutide and cagrilintide 15mg 5mg Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine CagriSema vs Tirzepatide: 23% Weight Loss in Phase 3 Trial